AISAP Cardio vs Autoplaque
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if your primary need is rapid, AI-powered cardiac diagnostic assessments at the point of care using ultrasound. This tool is ideal for clinicians requiring immediate, comprehensive interpretations of cardiac function and structural abnormalities directly at the patient's bedside, facilitating early detection of conditions like heart failure and valvular disease.
View AISAP Cardio →Choose Autoplaque if…
Choose Autoplaque if your focus is on detailed, quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This workstation-based software is best suited for cardiologists and radiologists who need to precisely characterize atherosclerotic plaque burden and severity to inform heart attack risk prediction and guide long-term treatment strategies.
View Autoplaque →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | Autoplaque |
|---|---|---|
| Deployment | Cloud-based | Workstation-based post-processing application, runs on Windows or Mac OS. |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio is a cloud-based SaaS platform designed for point-of-care use, offering seamless integration with existing clinical workflows, EHR/EMR, and PACS, making it highly accessible and adaptable. Its design enables non-cardiologists to interpret echocardiograms accurately with minimal training, enhancing its usability across various clinical settings. Autoplaque, while offering clinician-reviewable segmentation, is workstation-based, which can be less flexible for widespread deployment and immediate bedside diagnostics.
Clinical Value
AISAP CardioAISAP Cardio demonstrates superior clinical value by enabling early detection of structural heart disease and heart failure at the bedside with high sensitivity and specificity (93%) for major valve diseases. Its ability to empower non-cardiologists to accurately interpret echocardiograms, validated in clinical trials, significantly broadens access to critical cardiac diagnostics and has shown to change care pathways in a third of patients. While Autoplaque provides valuable quantitative plaque analysis from CT, AISAP Cardio's immediate, point-of-care impact on a broader range of cardiac conditions gives it an edge in overall clinical utility.
Pricing & Value
TieNeither AISAP Cardio nor Autoplaque publicly disclose their pricing information, requiring direct contact with the respective companies for details [JSON]. Without transparent pricing, it is impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition.
Enterprise Readiness
AISAP CardioAISAP Cardio is a cloud-based SaaS platform that is vendor-agnostic, scalable, and explicitly designed for seamless integration with EHR/EMR and PACS systems, demonstrating strong enterprise readiness [JSON, 2, 9, 14]. Furthermore, recent information confirms its HIPAA compliance, which is crucial for healthcare data handling. Autoplaque, being workstation-based, may present more challenges for large-scale deployment and centralized management within an enterprise environment, and explicit compliance details are not readily available [JSON, 1].
Innovation
AISAP CardioAISAP Cardio demonstrates higher innovation by pioneering AI-powered point-of-care ultrasound for comprehensive structural heart disease diagnosis, being the first to receive FDA clearance in this CADx pathway. Its ability to empower non-cardiologists with expert-level diagnostic capabilities at the bedside, leveraging extensive deep learning, represents a transformative shift in accessibility and speed of cardiac care. While Autoplaque's quantitative plaque analysis is innovative, AISAP Cardio's impact on democratizing advanced cardiac diagnostics at the point of care is arguably more groundbreaking.
Support & Docs
TieNeither AISAP Cardio nor Autoplaque provides sufficient public information regarding their specific support channels, service level agreements, or comprehensive user documentation. While both likely offer some form of support, the lack of transparent details prevents a meaningful comparison in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | Autoplaque |
|---|---|---|
| Name | AISAP Cardio | Autoplaque |
| Company | Aisap | Cedars-Sinai Medical Center: AIM |
| Description | FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. |
| Primary Modality | Point-of-Care Ultrasound (POCUS) | CT Angiography |
| Key Feature Focus | Early detection of structural heart disease and heart failure, assessment of valvular pathologies, LVEF, ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter. | Quantitative analysis of coronary plaques and luminal stenoses, heart attack risk prediction. |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and Autoplaque.